Abstract
Antibody therapies targeting the IL-4/IL-13 axis are used in type 2 inflammatory diseases affecting skin, airways, and gastrointestinal tissues. Clinical responses and biomarker behavior differ across organs, complicating trial interpretation and endpoint selection. We propose an IL-4Rα-centered framework that relates these differences to receptor-responsive cells, local cytokine supply, and the compartments sampled by each endpoint. Type I receptors (IL-4Rα/γc) support IL-4-dependent immune priming, including type 2 helper T-cell (Th2) differentiation and immunoglobulin E (IgE) class switching. Type II receptors (IL-4Rα/IL-13Rα1) respond to both IL-4 and IL-13 and are prominent in epithelial and mesenchymal effector programs. Selected immune populations also respond through Type II receptors. We connect receptor biology to organ-specific experimental mechanisms and clinical outcomes, distinguish within-cell receptor expression from tissue cellular composition, and consider IL-13Rα2 as a separate ligand-buffering regulator. These assignments are predominant tendencies rather than exclusive cellular localizations or validated treatment-selection rules. This approach links molecular, tissue, and clinical endpoints while avoiding claims of drug superiority based on cross-trial comparisons.

This publication has 111 references indexed in Scilit: